-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Oncorus, Inc. (NASDAQ:ONCR) Major Shareholder James E. Flynn Sells 99,718 Shares
Oncorus, Inc. (NASDAQ:ONCR) Major Shareholder James E. Flynn Sells 99,718 Shares
Oncorus, Inc. (NASDAQ:ONCR – Get Rating) major shareholder James E. Flynn sold 99,718 shares of the business's stock in a transaction that occurred on Monday, December 19th. The shares were sold at an average price of $0.29, for a total transaction of $28,918.22. Following the completion of the sale, the insider now directly owns 332,725 shares in the company, valued at $96,490.25. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Major shareholders that own 10% or more of a company's stock are required to disclose their transactions with the SEC.
Oncorus Stock Down 8.3 %
ONCR traded down $0.03 during trading hours on Wednesday, hitting $0.28. 86,612 shares of the company's stock were exchanged, compared to its average volume of 130,208. Oncorus, Inc. has a 12-month low of $0.27 and a 12-month high of $5.76. The firm has a 50 day moving average of $0.57 and a 200 day moving average of $1.04. The firm has a market cap of $7.27 million, a P/E ratio of -0.10 and a beta of 2.24. The company has a current ratio of 4.97, a quick ratio of 4.97 and a debt-to-equity ratio of 0.24.
Get Oncorus alerts:Oncorus (NASDAQ:ONCR – Get Rating) last posted its quarterly earnings results on Wednesday, November 2nd. The company reported ($0.76) EPS for the quarter, topping the consensus estimate of ($0.77) by $0.01. Analysts predict that Oncorus, Inc. will post -2.69 EPS for the current fiscal year.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently added to or reduced their stakes in ONCR. Millennium Management LLC acquired a new position in Oncorus during the 2nd quarter worth approximately $476,000. Renaissance Technologies LLC boosted its holdings in shares of Oncorus by 1,144.9% in the 1st quarter. Renaissance Technologies LLC now owns 175,532 shares of the company's stock valued at $312,000 after buying an additional 161,432 shares in the last quarter. Private Advisor Group LLC acquired a new position in shares of Oncorus in the 1st quarter valued at $112,000. Bank of New York Mellon Corp boosted its holdings in shares of Oncorus by 106.6% in the 1st quarter. Bank of New York Mellon Corp now owns 122,047 shares of the company's stock valued at $218,000 after buying an additional 62,985 shares in the last quarter. Finally, Sawtooth Solutions LLC acquired a new position in shares of Oncorus in the 1st quarter valued at $112,000. Institutional investors and hedge funds own 65.89% of the company's stock.Analyst Upgrades and Downgrades
A number of equities research analysts have recently issued reports on the stock. Piper Sandler downgraded shares of Oncorus from an "overweight" rating to a "neutral" rating and reduced their price target for the company from $6.00 to $2.00 in a research note on Wednesday, November 30th. Chardan Capital downgraded shares of Oncorus from a "buy" rating to a "neutral" rating in a research note on Wednesday, November 30th. Finally, HC Wainwright downgraded shares of Oncorus from a "buy" rating to a "neutral" rating in a research note on Tuesday, December 6th.
Oncorus Company Profile
(Get Rating)
Oncorus, Inc, a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers.
Read More
- Get a free copy of the StockNews.com research report on Oncorus (ONCR)
- Institutions Put Bottom In Rite Aid Shares
- Here's Why You Should Steer Clear of the FedEx Bounce
- Why Did Viking Therapeutics Stock Skyrocket
- NIKE, Inc Swooshes Higher On Results And Outlook
- Will AMC's Troubles Affect Its Landlord, EPR Properties?
Receive News & Ratings for Oncorus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncorus and related companies with MarketBeat.com's FREE daily email newsletter.
Oncorus, Inc. (NASDAQ:ONCR – Get Rating) major shareholder James E. Flynn sold 99,718 shares of the business's stock in a transaction that occurred on Monday, December 19th. The shares were sold at an average price of $0.29, for a total transaction of $28,918.22. Following the completion of the sale, the insider now directly owns 332,725 shares in the company, valued at $96,490.25. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Major shareholders that own 10% or more of a company's stock are required to disclose their transactions with the SEC.
Oncorus, Inc.（纳斯达克股票代码：ONCR — Get Rating）主要股东詹姆斯·弗林在12月19日星期一进行的一笔交易中出售了该公司的99,718股股票。这些股票的平均价格为0.29美元，总交易额为28,918.22美元。出售完成后，知情人现在直接拥有该公司的332,725股股票，价值96,490.25美元。该交易是在向美国证券交易委员会提交的法律文件中披露的，该文件可通过以下方式获得 美国证券交易委员会网站。拥有公司10％或更多股票的主要股东必须披露他们与美国证券交易委员会的交易。
Oncorus Stock Down 8.3 %
Oncorus 股票下跌 8.3%
ONCR traded down $0.03 during trading hours on Wednesday, hitting $0.28. 86,612 shares of the company's stock were exchanged, compared to its average volume of 130,208. Oncorus, Inc. has a 12-month low of $0.27 and a 12-month high of $5.76. The firm has a 50 day moving average of $0.57 and a 200 day moving average of $1.04. The firm has a market cap of $7.27 million, a P/E ratio of -0.10 and a beta of 2.24. The company has a current ratio of 4.97, a quick ratio of 4.97 and a debt-to-equity ratio of 0.24.
ONCR在周三交易时段下跌0.03美元，至0.28美元。该公司股票共交易86,612股，而平均交易量为130,208股。Oncorus, Inc.创下12个月低点0.27美元，12个月高点为5.76美元。该公司的50天移动平均线为0.57美元，200天移动平均线为1.04美元。该公司的市值为727万美元，市盈率为-0.10，beta值为2.24。该公司的流动比率为4.97，速动比率为4.97，债务与权益比率为0.24。
Oncorus (NASDAQ:ONCR – Get Rating) last posted its quarterly earnings results on Wednesday, November 2nd. The company reported ($0.76) EPS for the quarter, topping the consensus estimate of ($0.77) by $0.01. Analysts predict that Oncorus, Inc. will post -2.69 EPS for the current fiscal year.
Oncorus（纳斯达克股票代码：ONCR — Get Rating）最后一次公布季度财报是在11月2日星期三。该公司公布了本季度每股收益（0.76美元），比市场普遍预期的（0.77美元）高出0.01美元。分析师预测，Oncorus, Inc.将在本财年公布每股收益为-2.69。
Institutional Inflows and Outflows
机构流入和流出
Analyst Upgrades and Downgrades
分析师升级和降级
A number of equities research analysts have recently issued reports on the stock. Piper Sandler downgraded shares of Oncorus from an "overweight" rating to a "neutral" rating and reduced their price target for the company from $6.00 to $2.00 in a research note on Wednesday, November 30th. Chardan Capital downgraded shares of Oncorus from a "buy" rating to a "neutral" rating in a research note on Wednesday, November 30th. Finally, HC Wainwright downgraded shares of Oncorus from a "buy" rating to a "neutral" rating in a research note on Tuesday, December 6th.
许多股票研究分析师最近发布了有关该股的报告。派珀·桑德勒在11月30日星期三的一份研究报告中将Oncorus的股票评级从 “增持” 下调至 “中性”，并将该公司的目标股价从6.00美元下调至2.00美元。Chardan Capital在11月30日星期三的一份研究报告中将Oncorus的股票评级从 “买入” 下调至 “中性”。最后，HC Wainwright在12月6日星期二的一份研究报告中将Oncorus的股票评级从 “买入” 下调至 “中性”。
Oncorus Company Profile
Oncorus 公司简介
(Get Rating)
（获取评分）
Oncorus, Inc, a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers.
Oncorus, Inc是一家临床阶段的生物制药公司，专注于为癌症患者开发病毒免疫疗法。该公司的主要候选产品是 ONCR-177，这是一种基于溶瘤单纯疱疹病毒1型平台的肿瘤内给药的病毒免疫疗法，该平台正在进行治疗各种癌症的I期临床试验。
Read More
阅读更多
- Get a free copy of the StockNews.com research report on Oncorus (ONCR)
- Institutions Put Bottom In Rite Aid Shares
- Here's Why You Should Steer Clear of the FedEx Bounce
- Why Did Viking Therapeutics Stock Skyrocket
- NIKE, Inc Swooshes Higher On Results And Outlook
- Will AMC's Troubles Affect Its Landlord, EPR Properties?
- 免费获取 StockNews.com 关于 Oncorus（ONCR）的研究报告的副本
- 机构将 Rite Aid 股票触底
- 这就是为什么你应该避开联邦快递的反弹
- 为什么维京疗法的股票暴涨
- 耐克公司在业绩和展望方面大涨
- AMC的麻烦会影响其房东EPR财产吗？
Receive News & Ratings for Oncorus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncorus and related companies with MarketBeat.com's FREE daily email newsletter.
接收 Oncorus Daily 的新闻和评级 -在下面输入您的电子邮件地址，即可通过Marketbeat.com的免费每日电子邮件时事通讯接收Oncorus及相关公司的最新新闻和分析师评级的简明每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧